IL126787A - D-proline derivatives, medicaments against amyloidosis comprising them and a process for their preparation - Google Patents

D-proline derivatives, medicaments against amyloidosis comprising them and a process for their preparation

Info

Publication number
IL126787A
IL126787A IL12678798A IL12678798A IL126787A IL 126787 A IL126787 A IL 126787A IL 12678798 A IL12678798 A IL 12678798A IL 12678798 A IL12678798 A IL 12678798A IL 126787 A IL126787 A IL 126787A
Authority
IL
Israel
Prior art keywords
preparation
proline derivatives
medicaments against
amyloidosis
against amyloidosis
Prior art date
Application number
IL12678798A
Other languages
English (en)
Other versions
IL126787A0 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL126787A0 publication Critical patent/IL126787A0/xx
Publication of IL126787A publication Critical patent/IL126787A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IL12678798A 1997-10-31 1998-10-28 D-proline derivatives, medicaments against amyloidosis comprising them and a process for their preparation IL126787A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97119031 1997-10-31
EP98113851 1998-07-24

Publications (2)

Publication Number Publication Date
IL126787A0 IL126787A0 (en) 1999-08-17
IL126787A true IL126787A (en) 2003-12-10

Family

ID=26145860

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12678798A IL126787A (en) 1997-10-31 1998-10-28 D-proline derivatives, medicaments against amyloidosis comprising them and a process for their preparation

Country Status (35)

Country Link
US (4) US6103910A (pl)
EP (1) EP0915088B1 (pl)
JP (1) JP3048558B2 (pl)
KR (2) KR100313637B1 (pl)
CN (1) CN100357270C (pl)
AR (1) AR015473A1 (pl)
AT (1) ATE224366T1 (pl)
AU (1) AU750734B2 (pl)
BR (1) BR9804378B1 (pl)
CA (1) CA2252163C (pl)
CO (1) CO5011076A1 (pl)
CZ (1) CZ296252B6 (pl)
DE (1) DE69808017T2 (pl)
DK (1) DK0915088T3 (pl)
EG (1) EG23756A (pl)
ES (1) ES2182203T3 (pl)
HK (1) HK1019875A1 (pl)
HR (1) HRP980572B1 (pl)
HU (1) HUP9802465A1 (pl)
ID (1) ID21194A (pl)
IL (1) IL126787A (pl)
MA (1) MA26559A1 (pl)
MY (1) MY142803A (pl)
NO (1) NO312064B1 (pl)
PE (1) PE123499A1 (pl)
PL (1) PL196967B1 (pl)
PT (1) PT915088E (pl)
RS (1) RS49589B (pl)
RU (1) RU2201937C2 (pl)
SA (1) SA98190749B1 (pl)
SG (1) SG74094A1 (pl)
SI (1) SI0915088T1 (pl)
TR (1) TR199802197A2 (pl)
TW (1) TW585854B (pl)
UY (1) UY25230A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211731A1 (en) * 1999-05-05 2006-09-21 Les Laboratories Servier New substituted pyridine or piperidine compounds
FR2793245B1 (fr) * 1999-05-05 2002-10-11 Adir Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2001010836A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Method of treating hair loss using multivalent ketoamides and amides
CA2413418A1 (en) 2000-06-21 2001-12-27 Joseph B. Santella Piperidine amides as modulators of chemokine receptor activity
FI20011466A0 (fi) 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
EP1418905B1 (en) * 2001-08-08 2007-05-02 Pentraxin Therapeutics Limited Therapeutic agent for depletion of an unwanted protein population from plasma
GB0119370D0 (en) 2001-08-08 2001-10-03 Univ London Therapeutic agent
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
WO2003090680A2 (en) * 2002-04-23 2003-11-06 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
DE10240026A1 (de) * 2002-08-27 2004-03-11 Merck Patent Gmbh Verfahren zur Herstellung von Monoalkylaminoketonen
FI20030014A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
US7553819B2 (en) 2003-05-12 2009-06-30 Theracarb Inc. Multivalent inhibitors of serum amyloid P component
DE602004023080D1 (de) * 2003-05-20 2009-10-22 Novartis Ag N-acyl stickstoffheterocyclen als liganden von peroxisom-proliferator-aktivierten rezeptoren
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
DE102004010943A1 (de) * 2004-03-03 2005-09-29 Degussa Ag Verfahren zur Herstellung von N-geschützten 4-Ketprolinderivaten
ITMI20041567A1 (it) * 2004-07-30 2004-10-30 Maycos Italiana Di Comini Miro "derivati n-acilati di acidi bicarbossilici con amminoacidi e con idrolizzati proteici vegetali e loro applicazione in prodotti cosmetici, dermofarmaceutici e farmaceutici"
CN1834095B (zh) * 2005-03-18 2011-04-20 中国科学院上海药物研究所 一类非核苷类抗病毒抑制剂及其制备方法和用途
CA2619790A1 (en) 2005-08-17 2007-02-22 Schering Corporation Novel high affinity thiophene-based and furan-based kinase ligands
WO2008014232A2 (en) * 2006-07-24 2008-01-31 Emisphere Technologies, Inc. Pharmaceutical formulations for the treatment of alzheimer's disease
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use
GB2470187A (en) * 2009-05-11 2010-11-17 Pharmapatents Global Ltd Captopril polymers
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
UA108227C2 (xx) * 2010-03-03 2015-04-10 Антигензв'язуючий білок
EP2833739B1 (en) * 2012-03-30 2020-12-02 Givaudan SA N-acyl proline derivatives as food flavouring compounds
CN103333095B (zh) * 2013-06-26 2015-06-24 中国人民解放军第二军医大学 己二酰二d-羟脯氨酸衍生物及其作为核酸疫苗佐剂的应用
DE102013012622A1 (de) * 2013-07-30 2015-02-05 Clariant lnternational Ltd Neue sterisch gehinderte cyclische Amine
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
DE102015000124A1 (de) * 2015-01-07 2016-07-07 Clariant International Ltd. Verfahren zur Stabilisierung von Polyamiden
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
GB201518950D0 (en) * 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
CN116655512A (zh) * 2023-05-31 2023-08-29 江苏阿尔法药业股份有限公司 一种卡托普利的制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2328391A1 (de) * 1972-06-19 1974-01-10 Degussa Trialkoxycinnamoylaminocarbonsaeuren
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
AU509899B2 (en) * 1976-02-13 1980-05-29 E.R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
JPS53108922A (en) * 1977-03-04 1978-09-22 Sumitomo Chem Co Ltd Novel synthesis of opticallactive hydroxyacid
US4499102A (en) * 1979-12-13 1985-02-12 Santen Pharmaceutical Co., Ltd. Thiazolidine and pyrrolidine compounds and pharmaceutical compositions containing them
US4386075A (en) * 1982-02-17 1983-05-31 Smithkline Beckman Corporation Renally active tetrapeptides
CA1247086A (en) * 1982-02-17 1988-12-20 Francis R. Pfeiffer Renally active tetrapeptides
CA1333807C (en) * 1987-06-15 1995-01-03 David R. Kronenthal Process for preparing (trans)-4-phenyl-l-proline derivatives
JPH0832704B2 (ja) * 1987-11-30 1996-03-29 キッセイ薬品工業株式会社 プロリルエンドペプチダーゼ阻害剤
JPH01250370A (ja) * 1987-12-23 1989-10-05 Zeria Pharmaceut Co Ltd 新規アミノ酸イミド誘導体、製法ならびに用途
JPH02157262A (ja) * 1988-12-10 1990-06-18 Meiji Seika Kaisha Ltd 生理活性を有する新規なピロリジン誘導体
US4999417A (en) * 1989-03-30 1991-03-12 Nova Pharmaceutical Corporation Biodegradable polymer compositions
GB8912303D0 (en) * 1989-05-27 1989-07-12 Pfizer Ltd Therapeutic agents
US5439930A (en) * 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
JPH0661099A (ja) * 1992-08-05 1994-03-04 Mitsubishi Petrochem Co Ltd 電解コンデンサ駆動用電解液
JP3274247B2 (ja) * 1993-09-20 2002-04-15 杏林製薬株式会社 光学活性なインドリン誘導体の製法と中間体
FR2712888B1 (fr) * 1993-11-23 1996-02-09 Bioeurope Utilisation de alpha-D-alkylglucopyranosides et esters de ceux-ci pour la préparation de prodrogues capables de traverser la barrière hématoencéphalique, prodrogues obtenues et précurseurs de celles-ci.
JPH0840896A (ja) * 1994-08-04 1996-02-13 Teisan Seiyaku Kk カプトプリル類似体からなる医薬製剤
US6022885A (en) * 1995-09-15 2000-02-08 Smithkline Beecham P.L.C. Pyrrolidine and thiazole derivatives with antibacterial and . metallo-.beta-lactamase inhibitory properties
JPH09157251A (ja) * 1995-10-06 1997-06-17 Kanegafuchi Chem Ind Co Ltd N−(D−α−メチル−β−メルカプトプロピオニル)−L−プロリン及び該中間体の製造方法
AU1072897A (en) * 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta

Also Published As

Publication number Publication date
HUP9802465A1 (hu) 2000-12-28
CN1217327A (zh) 1999-05-26
DK0915088T3 (da) 2003-01-27
ID21194A (id) 1999-05-06
BR9804378A (pt) 2000-06-13
KR100342284B1 (ko) 2002-06-29
TR199802197A3 (tr) 1999-05-21
NO985059D0 (no) 1998-10-30
BR9804378B1 (pt) 2010-07-13
TR199802197A2 (xx) 1999-05-21
JPH11209343A (ja) 1999-08-03
DE69808017D1 (de) 2002-10-24
ATE224366T1 (de) 2002-10-15
HRP980572B1 (en) 2004-06-30
US6103910A (en) 2000-08-15
YU47698A (sh) 2001-07-10
AU8959998A (en) 1999-05-20
SG74094A1 (en) 2000-07-18
ES2182203T3 (es) 2003-03-01
PE123499A1 (es) 1999-12-13
CO5011076A1 (es) 2001-02-28
PL196967B1 (pl) 2008-02-29
HK1019875A1 (en) 2000-03-03
US6262089B1 (en) 2001-07-17
JP3048558B2 (ja) 2000-06-05
MA26559A1 (fr) 2004-12-20
UY25230A1 (es) 2001-01-31
CZ296252B6 (cs) 2006-02-15
RS49589B (sr) 2007-06-04
CA2252163C (en) 2008-09-09
KR19990037520A (ko) 1999-05-25
CA2252163A1 (en) 1999-04-30
US20030100770A1 (en) 2003-05-29
IL126787A0 (en) 1999-08-17
SI0915088T1 (en) 2002-12-31
SA98190749B1 (ar) 2006-05-13
KR100313637B1 (ko) 2002-01-12
DE69808017T2 (de) 2003-04-30
US6740760B2 (en) 2004-05-25
AU750734B2 (en) 2002-07-25
HU9802465D0 (en) 1998-12-28
MY142803A (en) 2011-01-14
EP0915088A1 (en) 1999-05-12
AR015473A1 (es) 2001-05-02
NO312064B1 (no) 2002-03-11
HRP980572A2 (en) 1999-08-31
TW585854B (en) 2004-05-01
CZ346398A3 (cs) 1999-05-12
KR20010083247A (ko) 2001-08-31
US6512001B1 (en) 2003-01-28
PL329440A1 (en) 1999-05-10
RU2201937C2 (ru) 2003-04-10
EG23756A (en) 2007-08-08
PT915088E (pt) 2003-01-31
NO985059L (no) 1999-05-03
CN100357270C (zh) 2007-12-26
EP0915088B1 (en) 2002-09-18

Similar Documents

Publication Publication Date Title
IL126787A (en) D-proline derivatives, medicaments against amyloidosis comprising them and a process for their preparation
SI0676409T1 (en) Erythromycin derivatives, their process for preparation and their application as medicaments
AP9500744A0 (en) New erythromycin derivatives, their process and their use as medicaments
GB9419536D0 (en) Medicaments
IL124350A (en) Resorcinyl-triazines, a process for their preparation and cosmetic compositions comprising them
HUP0002718A3 (en) Piperazine derivatives, process for their preparation and medicaments containing the same
GB9406573D0 (en) Medicaments
HRP960583B1 (en) New phenylamidine derivatives, a process for preparing the same and their use as medicaments
GB9420784D0 (en) Medicaments
ZA988285B (en) 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oles process for their preparation and their use for medicaments
HUP0104620A3 (en) 2-phenylpyran-4-one derivatives, process for their preparation and medicaments containing them
AU3011095A (en) 2,3-bridged 1,4-dihydropyridines, processes for their preparation and their use as medicaments
HUP9600665A2 (en) Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
IL120988A0 (en) Ortho-substituded benzoylguenidines process for their preparation their use as a medicament comprising them
HUP0001222A3 (en) Imino-aza-anthracyclinone derivatives, pharmaceutical compositions thereof against amyloidosis and process for preparing them
GR3035834T3 (en) Benzoxazindione derivatives, process for their preparation and their use
GB9418530D0 (en) Medicaments
GB9421133D0 (en) Medicaments
GB9411052D0 (en) Medicaments
GB9416365D0 (en) Medicaments
GB9424013D0 (en) Medicaments
GB9410621D0 (en) Medicaments
GB9414896D0 (en) Medicaments
GB9416645D0 (en) Medicaments
GB9417499D0 (en) Medicaments

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees